MSB 2.51% 97.0¢ mesoblast limited

Ann: Update on Scheduled FDA Advisory Committee Meeting, page-12

  1. 701 Posts.
    lightbulb Created with Sketch. 215
    "Mesoblast has extensively prepared for the meeting"
    "Ryoncil is under Priority review by the FDA"
    "There are currently no other FDA approved treatments"

    What else they could have said to calm down the nerves?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.